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Insect Bite Hypersensitivity in Horses is Associated with Airway
Hyperreactivity
S. Lanz , A. Brunner, C. Graubner, E. Marti, and V. Gerber
Background: Genetic and epidemiologic evidence suggests that in horses, as in other species, diﬀerent manifestations of
hypersensitivity may occur together.
Hypothesis: Horses aﬀected with insect bite hypersensitivity (IBH) show airway hyperreactivity (AH) to inhaled his-
tamine, even in the absence of overt clinical signs of equine asthma (EA).
Animals: Twenty-two healthy controls (group C), 24 horses suﬀering from IBH alone (group IBH), and 23 horses suﬀer-
ing from IBH and EA (group IBH/EA).
Methods: The clinical histories were assessed using 2 standardized questionnaires, the Horse Owner Assessed Respiratory
Signs Index (HOARSI), and IBH scoring. Horses were classiﬁed as EA-aﬀected if their HOARSI was >1 and as IBH-aﬀected
if IBH score was >0. Confounding disorders were excluded by clinical examination. The arterial partial pressure of oxygen
(PaO2) was measured and ﬂowmetric plethysmography used to assess airway reactivity to increasing doses of inhaled
histamine.
Results: The median histamine provocation concentration (PC) when Δﬂow values increased by 35% (PC35) was signiﬁ-
cantly higher in group C (5.94 [1.11–26.33] mg/mL) compared to group IBH (2.95 [0.23–10.13] mg/mL) and group IBH/EA
(2.03 [0.43–10.94] mg/mL; P < 0.01). The PC50 and PC75 showed very similar diﬀerences between groups. Furthermore,
PaO2 was signiﬁcantly lower in group IBH (84  8 mmHg) and group IBH/EA (78  11 mmHg) compared to group C
(89  6 mmHg; P < 0.01).
Conclusions and Clinical Importance: IBH is associated with AH and decreased PaO2, even in the absence of overt respira-
tory clinical signs.
Key words: Equine asthma; Horse; Insect bite hypersensitivity; Multiple equine allergies.
Recent genetic and epidemiologic evidence suggeststhat diﬀerent manifestations of hypersensitivity
may occur together in horses. Speciﬁcally, horses with
insect bite hypersensitivity (IBH) have been shown to
have a higher risk of being concurrently aﬀected by
recurrent airway obstruction (RAO), and vice versa.1
Although IBH is an allergic dermatologic disorder trig-
gered by allergens from Culicoides biting midges,2 RAO
is thought to be the result of a hypersensitivity to
inhaled allergens and represents the severe form of
equine asthma (EA). Equine asthma, a recently intro-
duced term, comprises the clinical severity spectrum
from mild (inﬂammatory airway disease, IAD) to severe
forms (RAO).3,4 In horses that are predisposed to EA,
inhaled allergens and irritants play a major role in the
development of cough, decreased performance, impaired
gas exchange, bronchoconstriction, and airway hyperre-
activity (AH).4
Human patients with asthma often also suﬀer from
dermatologic allergic hypersensitivities, such as atopic
dermatitis.5 These cutaneous manifestations of atopy
can mark the start of the so-called “atopic march” with
approximately two-thirds of patients with atopic der-
matitis later developing allergic rhinitis and half of them
progressing to asthma.5 Similar concurrences of diﬀer-
ent hypersensitivity manifestations in the same individu-
als also have been observed in cats with pruritic
dermatosis and feline asthma,6 in dogs with allergic der-
matitis, conjunctivitis, rhinitis, and asthma-like clinical
signs7 and recently in horses with RAO, IBH, and
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IL13 interleukin 13
MHS multiple hypersensitivities
PaO2 partial pressure of arterial oxygen
PC provocation concentration




J Vet Intern Med 2017;31:1877–1883
chronic recurrent urticaria.1 These ﬁndings suggest a
common immunogenetic background, route of sensitiza-
tion, or both leading to these multiple hypersensitivities
(MHS).
The outcome measures in the epidemiologic study of
horses described above1 were solely based on owner-
reported medical history. No further examinations
regarding the potential presence of respiratory abnor-
malities had been performed. Histamine bronchoprovo-
cation testing using ﬂowmetric plethysmography is an
objective tool, available in equine medicine, that can be
used to detect AH even in clinically normal horses.8,9
We, therefore, aimed to speciﬁcally examine the respira-
tory status of IBH-aﬀected horses with and without a
history of EA. Respiratory status was evaluated using
plethysmography with a bronchial histamine provoca-
tion test and arterial partial pressure of oxygen (PaO2).
Speciﬁcally, we hypothesized that IBH is accompanied
by increased AH, even in the absence of overt respira-
tory clinical signs.
Materials and Methods
Study Design and Horses
This study was approved by the ethical committees of the Can-
tons of Berne, Freiburg, Solothurn and Geneva, Switzerland
(BE10/13), and examinations were performed between March 2015
and July 2015.
The sample size calculation was based on raw data from
research in our group.10 To detect a decrease in provocation con-
centration (PC) when Mﬂow values increased by 35% compared to
saline (PC35) from 7.1 mg/mL (healthy horses) to 3.6  3.4 mg/
mL (aﬀected horses) at a 5% signiﬁcance level and power of 80%,
a sample size calculationa indicated that a minimal sample size of
15 per group would be required. The aim was therefore to recruit
at least 20 horses per group to account for potential dropouts.
Horses were recruited by way of an advertisement published in the
“Bulletin,” the oﬃcial monthly publication of the Swiss equine
sport and breeding associations. Additionally, the databases of the
Swiss Institute of Equine Medicine (ISME) and the Department of
Clinical Research of the University of Bern, Switzerland were
screened for IBH-aﬀected horses.
Potential candidates were examined either at their home stables
or at the clinic of the ISME in Berne. Horses were included if they
had a history compatible with IBH alone or IBH and EA (see
below). Healthy individuals of similar breed and sex distribution
also were recruited. Any animals showing signs of confounding
disorders (see below) were excluded. It was required that at the
time of examination, all horses were free of any medication that
might inﬂuence the outcome measures. Speciﬁcally, a washout per-
iod of at least 3 weeks was required for any previously adminis-
tered corticosteroids. Horses were divided into 3 subgroups:
healthy controls (group C), IBH-aﬀected animals (group IBH),
and IBH and EA-aﬀected animals (group IBH/EA) using a ques-
tionnaire-based classiﬁcation (see below).
Questionnaires and Classification Criteria
For every horse, IBH severity and lung health status were deter-
mined using standardized questionnaires.
The IBH score was based on a previously described question-
naire11 completed by the owner and based on the most severe clin-
ical signs the horse had experienced. Brieﬂy, cutaneous lesions
observed on the mane, tail head, ventral midline, or some combi-
nation of these were classiﬁed in 5 severity grades, each with an
additional characteristic compared to the preceding grade with
(0) no signs of IBH; (1) increased skin ﬂaking with visible epithe-
lial debris; (2) areas of broken hairs or alopecia from scratching;
(3) indurated skin folds; (4) obvious crusts from serous exudate,
but without bleeding; and (5) bleeding from self-inﬂicted abra-
sions. Owners also were asked if a seasonal pattern (consistent
with exposure to insects, that is, spring to fall exacerbation)
regarding the clinical signs was observed. Horses were classiﬁed as
IBH positive, if the IBH score was >0 and if they were seasonally
aﬀected. Because clinical signs of IBH are typical, 1 season of
observed clinical signs was suﬃcient to qualify.
The Horse Owner Assessed Respiratory Signs Index (HOARSI)
was used to grade EA severity, as described in detail in a previous
study.12 The HOARSI also referred to the most severe clinical
signs in the horse’s history. Horses graded HOARSI 1 were classi-
ﬁed as healthy, whereas HOARSI 2 (mild), HOARSI 3 (moder-
ate), and HOARSI 4 (severe) were consistent with EA.
To avoid false negative control animals as far as possible, all
horses had to have spent at least 1 warm season (spring to fall) in
Switzerland exposed to Culicoides and also, by deﬁnition, all
horses that were classiﬁed according to the HOARSI had been
exposed previously to hay for at least 2 months.
Clinical Examination
Horses underwent a thorough clinical examination that included
respiratory tract and cardiac auscultation, rectal temperature,
mucous membrane color, capillary reﬁll time, submandibular
lymph node palpation, and lung auscultation at rest and during
rebreathing to exclude confounding disorders. Furthermore, blood
was collected from the common carotid artery before the rebreath-
ing examination for determination of PaO2 (i-STAT
 Portable
Clinical Analyzeb ).
Histamine Bronchoprovocation with Plethysmography
To characterize airway reactivity, a pulmonary function test,
with ﬂowmetric plethysmography (Open Pleth Systemc )9 with his-
tamine bronchoprovocation13 was used. The horses were sedated
with detomidined IV (Equisedan, 0.01–0.02 mg/kg) and ﬁtted with
an airtight mask and a pneumotachograph. In addition, 2 respira-
tory inductance bands were placed at the 11th intercostal space
and just behind the last rib, respectively. Subsequently, calibration
of the system was performed, after the manufacturer’s instructions.
Baseline measurements were recorded for 2 minutes, and then ster-
ile 0.9% saline solution was nebulized (negative control) with the
compressor and nebulizer provided with the system to generate a
particle size <4 lm, followed by another 3-minute recording. If
baseline Δﬂow exceeded 3.5 L/s (Δﬂow is the maximum diﬀerence
between the ﬂows measured by the pneumotachograph compared
to the calibrated ﬂow from the bands) or the Δﬂow increased more
than 50% compared to baseline after saline administration, mea-
surements were stopped, and no histamine was inhaled. Otherwise,
histamine (histamine diphosphate monohydrate)e in saline then
was nebulized in doubling concentrations (2, 4, 8, 16, 32 mg/mL).
After each dose of histamine, measurements were recorded for
3 minutes. This procedure was continued until 1 of the following
conditions was achieved: (1) the highest concentration (32 mg/mL)
of histamine was reached; (2) an increase of > 50% in Δﬂow values
from saline measurement was registered; (3) the horse showed
markedly increased abdominal breathing; or (4) the horse started
to cough repeatedly. The histamine challenge score (HCS) referred
to the concentration of histamine when the inhalation was stopp-
ed with (1) =32 or 16 mg/mL, (2) =8 mg/mL, (3) =4 mg/mL,
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(4) =2 mg/mL, and (5) =no histamine inhalation possible. No his-
tamine inhalation was possible when airway obstruction with
increased breathing eﬀort, excessive coughing, or both were
observed at baseline measurements or after saline inhalation.
When the inhalation protocol was completed, the software of the
Open Pleth System also provided the PC35, PC50, and PC75 using
log-linear interpolation of the dose–response curve.
Statistics
Analyses were performed with the statistical package NCSS
2007.f Descriptive statistics are reported as mean  standard devi-
ation (SD) or median (range) as appropriate. Normality was
assessed with the Skewness and Kurtosis (Omnibus) test. For com-
parisons among the 3 groups, one-way ANOVA was used for nor-
mally distributed data (PaO2) or Kruskal–Wallis one-way
ANOVA on ranks for non-normally distributed and ranked data
(PC35, PC50, PC75; HCS). The a-level of statistical signiﬁcance
was set at P < 0.05. For post hoc testing, Kruskal–Wallis multi-
ple-comparison z-value test (Dunn’s test) with z-value > 1.96 indi-
cating a P-value < 0.05 (Bonferroni test) was used. To assess
group diﬀerences regarding the categoric values sex and breed (Ice-
landic versus non-Icelandic), Fisher’s exact test was used.
Results
Signalment and Clinical Examination
A total of 69 horses (41 geldings, 25 mares, 3 stal-
lions) was recruited. There were 22 horses assigned to
group C, 24 to group IBH, and 23 to group IBH/EA.
Sex distribution (male [stallions and geldings combined]
versus female; P = 0.98) and age of group IBH (11 [4–
24] years), group IBH/EA (14 [3–27] years), and group
C (13 [5–25] years; P = 0.36) did not signiﬁcantly diﬀer
between groups. There were no diﬀerences between the
groups regarding the distribution of Icelandic horses
versus other breeds (P = 0.36). A total of 29 Icelandic
horses was included. The other breeds included Shet-
land Ponies (n = 7), Swiss Warmbloods (n = 6),
Freibergers (n = 6), Arabians (n = 3), Friesians (n = 2),
Polo Ponies (n = 2), Tinkers (n = 2), a Connemara
Pony, a Pinto, a Purebred Spanish Horse, an American
Quarter Horse, a Westphalian horse, and mixed breeds
(n = 7). Group C and group IBH contained 11 Ice-
landic horses each, whereas group IBH/EA included of
seven Icelandic horses. No horses were excluded based
on clinical signs suggestive of confounding disorders.
Overall, the severity grades of the cutaneous lesions of
IBH-aﬀected horses (distribution was similar between
IBH alone and IBH/EA) were as follows: 1 (n = 2); 2
(n = 18); 3 (n = 3); 4 (n = 4); and, 5 (n = 20).
Histamine Bronchoprovocation with Plethysmography
Baseline Δﬂow measurements did not diﬀer among
group C (n = 21; 1.01 [0.25–3.29] L/s), group IBH
(n = 17; 0.77 [1.26–7.61] L/s), and group IBH/EA
(n = 12; 1.15 [0.45–3.90] L/s; P = 0.43). However, no
histamine provocation was performed in 3 horses in
group IBH and another 8 in IBH/EA, because the max-
imal Δﬂow values at baseline exceeded 3.5 L/s or because
Δﬂow increased >50% compared to baseline after
administration of saline. In 1 additional horse in group
C, 4 horses in IBH, and 3 in IBH/EA, bronchoprovoca-
tion measurements were not possible because of techni-
cal problems (eg, software failure to calculate PC
values), repeated coughing or both.
The PC35 values were higher in group C (n = 21;
5.94 [1.11–26.33] mg/mL) compared to group IBH
(n = 17; 2.95 [0.23–10.13] mg/mL) and group IBH/EA
(n = 12; 2.03 [0.43–10.94] mg/mL; P < 0.01). Compar-
ison among the 3 groups showed that group C was dif-
ferent from group IBH (z-value: 2.10) and group IBH/
EA (z-value: 2.74). Group IBH and group IBH/EA did
not diﬀer (z-value: 0.81). However, group size for IBH/
EA in this comparison was below the calculated n = 15
necessary to detect a diﬀerence between the IBH group
and the IBH/EA group with a power of 80%.
Figure 1 illustrates the PC35 values of the diﬀerent
groups. The PC50 and PC75 values showed results simi-
lar to those of PC35 (see Figures S1 and S2).
Distribution of Maximal Doses Reached
The median histamine challenge score (HCS) of
group C was signiﬁcantly lower (n = 22; 1 [1–3]) than
that of group IBH (n = 24; 2.5 [1–5]) and group IBH/
EA (n = 23; 4 [1–5]). Comparison among the three
groups (z-value > 1.96 = P < 0.05) indicated that
group C was diﬀerent from group IBH (z-value: 3.24)
and group IBH/EA (z-value: 5.06). Group IBH and
group IBH/EA did not show a diﬀerence (z-value:
Fig 1. Box plot illustrating the provocation concentrations (PC)
when Δﬂow values increased by 35% (PC35) compared to baseline
of healthy controls (C) (n = 21; 5.94 [1.11–26.33] mg/mL), horses
suﬀering from insect bite hypersensitivity (IBH) (n = 17; 2.95
[0.23–10.13] mg/mL], and horses diagnosed with both IBH and
equine asthma (IBH/EA) (n = 12; 2.03 [0.43–10.94]). *Indicates
signiﬁcant diﬀerence compared to C.
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1.89). The numbers of horses achieving the diﬀerent
HCS in each group are illustrated in Figure 2.
Partial Pressure of Arterial Oxygen
Group C had a higher resting PaO2 (89  6 mmHg)
than both group IBH (84  8 mmHg) and group IBH/
EA (78  11 mmHg). Comparison among the 3 groups
(z-value > 1.96 = P < 0.05) indicated that group C was
diﬀerent from group IBH (z-value: 2.05) and group
IBH/EA (z-value: 4.16). Group IBH and group IBH/
EA also were diﬀerent (z-value: 2.16, Fig 3).
Discussion
Our results indicate that IBH is associated with AH.
Although this ﬁnding conﬁrms our hypothesis, it is sur-
prising, because these 2 hypersensitivity disorders aﬀect
separate organ systems. However, previous epidemio-
logic investigations in 2 distinct populations showed
that horses suﬀering from the dermatologic disorders
IBH or urticaria had an increased risk of also being
aﬀected by RAO, and vice versa.1
Histamine provocation clearly separated the IBH/EA
group from the control group. Most interestingly, group
IBH, the horses of which did not show overt clinical
signs of EA, also displayed signiﬁcantly decreased
PC35, 50, and 75 as well as lower PaO2 values than the
control group. Our study thus demonstrates that an
allergic skin disorder can be accompanied by AH
indicative of a subclinical eﬀect on the lower respiratory
tract.
However, PC values varied considerably within the
groups and overlapped among groups as illustrated in
Figure 1. Therefore, isolated PC values from single
horses cannot accurately predict the EA or the IBH sta-
tus of an individual animal.
Equine asthma had not been identiﬁed by the owners
in this group because the inclusion criteria required that
the owners had not noted any coughing, nasal dis-
charge, or increased respiratory eﬀort (HOARSI 1).
The HCS, which was possible to assess in all horses,
conﬁrmed the calculated PC values, where a number of
measurements had to be discarded. From our data, it
was not possible to draw sound conclusions on the
eﬀect of IBH severity on airway reactivity, because of
the small numbers of horses in some of the IBH score
groups.
In humans, investigations into the immunogenetic
background of these MHS disorders showed evidence
for speciﬁc genetic determinants as a potential underly-
ing reason for a general allergic phenotype.14 One can-
didate gene involved in diﬀerent allergic diseases,
speciﬁcally asthma, atopic dermatitis, and rhinitis, is
interleukin-4 receptor a-chain (IL4RA). In EA, a
genetic association between a region on equine chromo-
some (ECA) 13, containing the gene for IL4RA, and
RAO was described in a high-prevalence RAO fam-
ily.15,16 A linkage between RAO and a single nucleotide
polymorphism (SNP BIEC2-224511) on ECA 13 near
IL4RA was conﬁrmed in unrelated horses.17 However,
this polymorphism was not associated with MHS in
horses in a recent study.1
Additional genetic variants that might be associated
with both airway hypersensitivities and skin allergies
are polymorphisms in IL13, a gene playing the same
role in the T-helper-2 (Th2)-type response as IL4RA,
and a mutation in a proﬁlaggrin/ﬁlaggrin gene.18,19 The
IL13 polymorphisms have been associated with both
asthma and rhinitis, suggesting a common etiologic
pathway for their development.18,20 Furthermore, these
studies also showed an interaction between IL13 and
IL4R polymorphisms in asthma. However, even though
the RAO-associated quantitative trait locus on equine
Fig 2. Bar graph illustrating the number of horses assigned a par-
ticular histamine challenge score (HCS). The histamine challenge
score (HCS) refers to the dose of histamine when the inhalation
was stopped with HCS1 = 32 or 16 mg/mL, HCS2 = 8 mg/mL,
HCS3 = 4 mg/mL, HCS4 = 2 mg/mL, and HCS5 = no histamine
inhalation possible. *indicates signiﬁcant diﬀerence compared to
group C.
Fig 3. Box plots revealing the partial pressure of arterial oxygen
(PaO2) of healthy horses (C) (n = 22; 89  6 mmHg), horses suf-
fering from insect bite hypersensitivity (IBH) (n = 24,
84  8 mmHg), and horses suﬀering from both IBH and equine
asthma (IBH/EA) (n = 23, 78  11 mmHg). *Indicates a signiﬁ-
cant diﬀerence compared to group C. # indicates a signiﬁcant dif-
ference between group IBH and IBH/EA.
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chromosome 13 has triggered these investigations into
MHS in horses, RAO and IBH exhibit important
immunopathologic diﬀerences that must be considered
in the context of genes such as IL13 or IL4RA. Impor-
tantly, IBH is characterized as a type I allergy with
IgE- and Th2-type driven immunopathogenesis, and
lesional eosinophil and mast cell involvement.2
The immunopathology of RAO, in contrast, is still
unclear. Many contradictory results regarding a Th1-
Th2- Th17 or mixed immune response have been
reported.3
A further interesting candidate gene in humans with
MHS is ﬁlaggrin,21 which is not directly involved in
immune function, but rather in integrity of epithelial
barrier function.5 Cutaneous manifestations of atopy
often represent the beginning of the atopic march in
humans,21 and data from experimental animals as well
as from clinical studies in humans suggest a role for the
skin as an important route of sensitization to asthma-
inducing allergens.22 These ﬁndings support the concept
that skin barrier dysfunction increases the risk of sensi-
tization to allergens by facilitating crossing of the epi-
dermal barrier by environmental allergens and
subsequent induction of sensitization. In horses, there is
presently no published data on a possible involvement
of ﬁlaggrin mutations in IBH or RAO.
However, both RAO and IBH are genetically com-
plex diseases. The heritability of IBH susceptibility has
been reported in several breeds including Icelandic
horses, Friesian horses, Shetland ponies, and Belgian
Warmblood horses with a wide range from 0 to 0.36 on
the observed scale.15,23–27 Additional studies may
explore some of the candidate genes such as ﬁlaggrin. It
is very likely that multiple, even numerous genes are
involved in these disorders and it must be determined
which genes overlap and play a role in both hypersensi-
tivity manifestations. Other potential causes for multiple
allergies include epigenetic regulation as well as the gas-
trointestinal, respiratory tract and skin microbiome,
which are postulated to play important roles in allergies
in humans.28
Group classiﬁcations in our study were based on
owner-reported history using standardized scores. Previ-
ous studies have extensively described and validated the
HOARSI scoring system in several populations with
diﬀerent degrees of EA.10,12,29 The results of these
experiments suggest that horses with HOARSI 3 and 4
(regular to permanent coughing, increased breathing
eﬀort after work and, in HOARSI 4, also at rest) suﬀer
from RAO, whereas HOARSI 2 corresponds best with
IAD and HOARSI 1 indicates a clinically healthy lower
respiratory tract. The latter 2 categories are less distinct
however, making HOARSI a valuable, but imperfect
surrogate marker for EA. Accordingly, in future stud-
ies, it might be interesting to investigate if the diﬀerence
in hyperreactivity between IBH and IBH/EA is more
marked if a larger group of severely EA (RAO)-aﬀected
horses (ie, HOARSI 3 and 4) is studied.
It would have been useful to perform endoscopy to
assess the mucus quantity in the trachea and collect
bronchoalveolar ﬂuid (BALF) for cytology. This is
likely the main limitation of our study. Although the
HOARSI provides a validated scoring system, it is still
only a surrogate marker for EA. Current deﬁnitions of
RAO and IAD are based on cytologic variable, and the
relationship between hypersensitivity and cytology is
still unclear.4,30 Some studies have reported AH pre-
dominantly in mast cell-type or eosinophilic IAD,4
which might ﬁt with the atopic, Th2-primed immune
response observed in IBH,2,31 but a recent report did
not conﬁrm these associations.32
Endoscopy and BALF cytology were not performed
because owner compliance was particularly challenging,
and the number of participating horses would have
been insuﬃcient if these slightly more invasive proce-
dures would have been required. Furthermore, most
horses were examined at their home stables, making
additional examinations logistically challenging. How-
ever, we aimed to characterize horses as comprehen-
sively as possible under the given conditions. The
HOARSI scoring system was complemented by a thor-
ough clinical examination, resting arterial oxygen ten-
sion measurements, baseline lung function
measurements, and bronchoprovocation with histamine.
The IBH scoring system used worked well in our hands
and, as far as we are aware, there are no other pub-
lished scoring systems for IBH. For an additional more
in-depth classiﬁcation of IBH, future studies could use
a validated cellular antigen stimulation test, and the
period between the most severe historic clinical signs
and time of examination could be more standardized.33
Finally, we only examined horses for allergic reactions
involving the skin and the lungs (ie, IBH and EA). No
other organ systems were evaluated for potential hyper-
sensitivity disorders. Additional investigations concern-
ing MHS in horses, therefore, are needed. For instance,
it would be interesting to explore whether horses with
urticaria, which also was shown to be associated with
RAO,1 also suﬀer from hyperreactive airways or if
food-related allergies, such as the recently described glu-
ten hypersensitivity in horses,34 play a role in MHS.
In conclusion, the airways of horses with IBH alone
showed hyperreactivity similar to airways of horses with
EA. Although future studies may identify the immuno-
genetic basis for this phenomenon, our results already
suggest that horses suﬀering from IBH have a higher
risk for AH and therefore might be predisposed to
develop EA in the future. These ﬁndings should be
taken into account when evaluating IBH-horses pre-
sented for subtle respiratory signs.
Footnotes
a http://clincalc.com/stats/samplesize.aspx
b Abbott Point of Care Inc., Princeton, New Jersey, USA.
c Ambulatory Monitoring, Inc., Ardsley, New York, USA.
d Dr E. Graeub AG, Berne, Switzerland.
e NCSS Statistical Software, Kaysville, Utah, USA.
f Christoﬀel-Apotheke, Berne, Switzerland.
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Supporting Information
Additional Supporting Information may be found
online in the supporting information tab for this article:
Figure S1. Box plot illustrating the provocation con-
centrations (PC) when Δﬂow values increased by 50%
(PC50) compared to baseline of healthy controls (C)
(n = 21; 6.71 [1.59–38.79] mg/mL), horses suﬀering
from insect bite hypersensitivity (IBH) (n = 17; 3.11
[0.32–12.53] mg/mL) and horses diagnosed with both
IBH and equine asthma (IBH/EA) (n = 12; 2.45 [0.61–
11.53]). *Indicates signiﬁcant diﬀerence compared to C.
Figure S2. Box plot illustrating the provocation con-
centrations (PC) when Δﬂow values increased by 75%
(PC75) compared to baseline of healthy controls (C)
(n = 20; 8.77 [2.53–32.60] mg/mL), horses suﬀering
from insect bite hypersensitivity (IBH) (n = 17; 4.28
[0.48–16.54] mg/mL) and horses diagnosed with both
IBH and equine asthma (IBH/EA) (n = 12; 3.24
[0.0.91–12.50]). *Indicates signiﬁcant diﬀerence com-
pared to C.
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